Advertisement

Narcolepsy treatment: pharmacological and behavioral strategies in adults and children

  • Christian Franceschini
  • Fabio Pizza
  • Elena Antelmi
  • Maria Claudia Folli
  • Giuseppe PlazziEmail author
Neurology • Review
  • 40 Downloads
Part of the following topical collections:
  1. Excessive Daytime Sleepiness

Abstract

Narcolepsy is a disabling, rare, and chronic sleep disorder, currently classified as distinct central nervous system hypersomnia in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Although today a reliable pathogenic hypothesis identifies the cause of NT1 as an autoimmune process destroying hypocretin-producing cells, there is no cure for narcolepsy, and the symptomatic pharmacological available treatments are not entirely effective for all symptoms. Behavioral therapies play a synergistic role in the disease treatment. We here review the available therapeutic options for narcolepsy, including symptomatic pharmacological treatments as well as behavioral and psychosocial interventions that could help clinicians improve the quality of life of patients with narcolepsy in adulthood and childhood.

Keywords

Narcolepsy Adults Children Pharmacological treatment Psychological treatment Behavioral treatment 

Notes

Acknowledgments

Huge gratitude must be recognized to the memory of President of AIN, Icilio Ceretelli, who opened many eyes about real everyday challenges that narcoleptic patients and their families have to face and provided every person in need with the support they deserve.

Funding

This work was supported by the FFABR (Franceschini).

Compliance with ethical standards 

The work is a literature review and complied with the tenets of the Declaration of Helsinki, as well as with the ethical standards of the journal.

Conflict of interest

 Giuseppe Plazzi participated in advisory board for UCB Pharma, Jazz pharmaceuticals, Bioprojet, and Idorsia outside the submitted work. The other authors have no potential financial conflict of interest to disclose.

References

  1. 1.
    AASM: American Academy of Sleep Medicine (2014) ICSD-3: international classification of sleep disorders, 3rd edn. American Academy of Sleep Medicine, DanielGoogle Scholar
  2. 2.
    Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DNC, Smith MI, Piper DC, Hunter AJ, Porter RA, Upton N (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. PNAS 96:10911–10916.  https://doi.org/10.1073/pnas.96.19.10911 CrossRefPubMedGoogle Scholar
  3. 3.
    Sutcliffe JG, de Lecea L (2000) The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 62:161–168.  https://doi.org/10.1002/1097-4547(20001015)62:2<161::AID-JNR1>3.0.CO;2-1 CrossRefPubMedGoogle Scholar
  4. 4.
    Brown RE, Sergeeva O, Eriksson KS, Haas H (2001) Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 40:457–459.  https://doi.org/10.1016/S0028-3908(00)00178-7 CrossRefPubMedGoogle Scholar
  5. 5.
    Dye TJ, Gurbani N, Simakajornboon N (2018) Epidemiology and pathophysiology of childhood narcolepsy. Paediatr Respir Rev 25:14–18.  https://doi.org/10.1016/j.prrv.2016.12.005 CrossRefPubMedGoogle Scholar
  6. 6.
    Shibata M, Mondal MS, Date Y, Nakazato M, Suzuki H, Ueta Y (2008) Distribution of orexins-containing fibers and contents of orexins in the rat olfactory bulb. Neuroscience research, 61-99-105.  https://doi.org/10.1016/j.neures.2008.01.017
  7. 7.
    Tashiro T, Kanbayashi T, Iijima S, Hishikawa Y (1992) An epidemiological study of narcolepsy in Japanese. J Sleep Res 1:228Google Scholar
  8. 8.
    Mignot E (1998) Genetic and familial aspects of narcolepsy. Neurology 50:S16–S22.  https://doi.org/10.1212/WNL.50.2_Suppl_1.S16 CrossRefPubMedGoogle Scholar
  9. 9.
    Baumann CR, Mignot E, Lammers GJ, Overeem S, Arnulf I, Rye D, Dauvilliers Y, Honda M, Owens JA, Plazzi G, Scammell TE (2014) Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 37:1035–1042.  https://doi.org/10.5665/sleep.3756 CrossRefPubMedGoogle Scholar
  10. 10.
    Miyagawa T, Tokunaga K (2019) Genetics of narcolepsy. Hum Genome Var 6:4.  https://doi.org/10.1038/s41439-018-0033-7 CrossRefPubMedGoogle Scholar
  11. 11.
    Postiglione E, Antelmi E, Pizza F, Lecendreux M, Dauvilliers Y, Plazzi G (2018) The clinical spectrum of childhood narcolepsy. Sleep Med Rev 38:70–85.  https://doi.org/10.1016/j.smrv.2017.04.003 CrossRefPubMedGoogle Scholar
  12. 12.
    Dauvilliers Y, Jaussent I, Krams B, Scholz S, Lado S, Levy P, Pepin JL (2012) Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS One 7:e38977.  https://doi.org/10.1371/journal.pone.0038977 CrossRefPubMedGoogle Scholar
  13. 13.
    Fortuyn HA, Mulders PC, Renier WO, Buitelaar JK, Overeem S (2011) Narcolepsy and psychiatry: an evolving association of increasing interest. Sleep Med 12:714–719.  https://doi.org/10.1016/j.sleep.2011.01.013 CrossRefPubMedGoogle Scholar
  14. 14.
    Rocca FL, Pizza F, Ricc E, Plazzi G (2015) Narcolepsy during childhood: an update. Neuropediatrics 46:181–198.  https://doi.org/10.1055/s-0035-1550152 CrossRefPubMedGoogle Scholar
  15. 15.
    Ingravallo F, Gnucci V, Pizza F, Vignatelli L, Govi A, Dormi A, Pelotti S, Cicognani A, Dauvilliers Y, Plazzi G (2012) The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. Sleep Med 13:1293–1300.  https://doi.org/10.1016/j.sleep.2012.08.002 CrossRefPubMedGoogle Scholar
  16. 16.
    Ton TG, Watson NF, Koepsell TD, Longstreth WT (2014) Narcolepsy and the sickness impact profile: a general health status measure. Sleep Sci 7:5–12.  https://doi.org/10.1016/j.slsci.2014.07.001 CrossRefPubMedGoogle Scholar
  17. 17.
    Scammell TE, Estabrooke IV, McCarthy MT et al (2000) Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20:8620–8628.  https://doi.org/10.1523/JNEUROSCI.20-22-08620.2000 CrossRefPubMedGoogle Scholar
  18. 18.
    Wisor J (2013) Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol 4:139.  https://doi.org/10.3389/fneur.2013.00139 CrossRefPubMedGoogle Scholar
  19. 19.
    Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, Pollmächer T, Reading P, Sonka K; EFNS Task Force (2006) EFNS Task Force. EFNS guidelines on management of narcolepsy. Eur J Neurol 13:1035–1048.  https://doi.org/10.1111/j.1468-1331.2006.01473.x
  20. 20.
    Morgenthaler TI, Kapur VK, Brown T et al (2007) Standards of practice committee of the AASM. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 30:1705–1711.  https://doi.org/10.1093/sleep/30.12.1750 CrossRefPubMedGoogle Scholar
  21. 21.
    Schwartz JR, Feldman NT, Bogan RK (2005) Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. J Neuropsychiatry ClinNeurosci 17:405–412.  https://doi.org/10.1176/jnp.17.3.405 CrossRefGoogle Scholar
  22. 22.
    Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ (2003) Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 26:252–257CrossRefPubMedGoogle Scholar
  23. 23.
    Schwartz JR, Nelson MT, Schwartz ER, Hughes RJ (2004) Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol 27:74–79CrossRefPubMedGoogle Scholar
  24. 24.
    Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS, Lubin S (1994) Modafinil: a double-blind multicentric study. Sleep 17:S107–S112CrossRefPubMedGoogle Scholar
  25. 25.
    Broughton RJ, Fleming JA, George CF et al (1997) Randomized, doubleblind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49:444–451CrossRefPubMedGoogle Scholar
  26. 26.
    Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group (2000). Neurology 54:1166–1175.  https://doi.org/10.1212/WNL.54.5.1166
  27. 27.
    Beusterien KM, Rogers AE, Walsleben JA, Emsellem HA, Reblando JA, Wang L, Goswami M, Steinwald B (1999) Health- related quality of life effects of modafinil for treatment of narcolepsy. Sleep 22:757–765CrossRefPubMedGoogle Scholar
  28. 28.
    Palovaara S, Kivistö KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K (2000) Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam l-hydroxylation. Br J Clin Pharm 50:333–337.  https://doi.org/10.1046/j.1365-2125.2000.00271.x CrossRefGoogle Scholar
  29. 29.
    Kallweit U, Bassetti CL (2017) Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother 18:809–817.  https://doi.org/10.1007/s11940-015-0347-4 CrossRefPubMedGoogle Scholar
  30. 30.
    Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, Niebler GE, Roth T (2006) The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 22:761–774.  https://doi.org/10.1185/030079906X100050 CrossRefPubMedGoogle Scholar
  31. 31.
    Lin J-S, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC (2008) An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patients. Neurobiol Dis 30:74–83.  https://doi.org/10.1016/j.nbd.2007.12.003 CrossRefPubMedGoogle Scholar
  32. 32.
    Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomized trial. Lancet Neurol 12:1068–1075.  https://doi.org/10.1016/S1474-4422(13)70225-4 CrossRefPubMedGoogle Scholar
  33. 33.
    Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC, Poluektov M, Yakupov E, Kalinkin A, Aksu M, Yilmaz H, Benbir G, Wolynczyk-Gmaj D, Jernajczyk W, Staykov I, Tavarari AN (2017) Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:200–207.  https://doi.org/10.1016/S1474-4422(16)30333-7 CrossRefGoogle Scholar
  34. 34.
    Syed YY (2016) Pitolisant: first global approval. Drugs 76:1313–1318.  https://doi.org/10.1007/s40265-016-0620-1 CrossRefPubMedGoogle Scholar
  35. 35.
    Mamelak M, Escriu JM, Stokan O (1977) The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry 12:273–288PubMedGoogle Scholar
  36. 36.
    Roth T, Dauvilliers Y, Guinta D, Alvarez-Horine S, Dynin E, Black J (2017) Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res 26:407–414.  https://doi.org/10.1111/jsr.12468 CrossRefPubMedGoogle Scholar
  37. 37.
    Houghton WC, Scammell TE, Thorpy M (2004) Pharmacotherapy for cataplexy. Sleep Med Rev 8:355–366.  https://doi.org/10.1016/j.smrv.2004.01.004 CrossRefPubMedGoogle Scholar
  38. 38.
    Mansukhani M, Kotagal S (2012) Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective study. Sleep Med 13:606–610.  https://doi.org/10.1016/j.sleep.2011.10.032 CrossRefPubMedGoogle Scholar
  39. 39.
    Dauvilliers Y, Carlander B, Rivier F (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56:905–908.  https://doi.org/10.1002/ana.20339 CrossRefPubMedGoogle Scholar
  40. 40.
    de Oliveira MM, Conti C, Prado GF (2016) Pharmacological treatment for Kleine Levin syndrome. Cochrane Database Syst Rev 25:486–496.  https://doi.org/10.1002/14651858.CD006685.pub4.2016 CrossRefGoogle Scholar
  41. 41.
    Leu-Semenescu S, Le Corvec T, Groos E, Lavault S, Golmard JL, Arnulf I (2015) Lithium therapy in Kleine-Levin syndrome: an open-label, controlled study in 130 patients. Neurology 85:1655–1662.  https://doi.org/10.1212/WNL.0000000000002104 CrossRefPubMedGoogle Scholar
  42. 42.
    Trotti LM, Saini P, Bliwise DL, Freeman AA, Jenkins A, Rye DB (2015) Clarithromycin in ɣ-aminobutyric acid-related hypersomnolence: a randomized, cross-over trial. Ann Neurol 78:454–465.  https://doi.org/10.1002/ana.24459 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
  44. 44.
    Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP (1986) Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 9:260–264.  https://doi.org/10.1093/sleep/9.1.260 CrossRefPubMedGoogle Scholar
  45. 45.
    Honda Y, Hishikawa Y, Takahashi Y (1979) Long-term treatment of narcolepsy with methylphenidate (Ritalin). Curr Ther Res 25:288–298Google Scholar
  46. 46.
    Leonard BE, McCartan D, White J, King DJ (2004) Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 19:151–180.  https://doi.org/10.1002/hup.579 CrossRefGoogle Scholar
  47. 47.
    Mignot EJ (2012) A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 9:739–752.  https://doi.org/10.1007/s13311-012-0150-9 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Mayer G, Meier-Ewert K, Hephata K (1995) Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 18:306–319CrossRefGoogle Scholar
  49. 49.
    Larrosa O, de la Llave Y, Barrio S, Granizo JJ, Garcia-Borreguero D (2001) Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 24:282–285.  https://doi.org/10.1093/sleep/24.3.282 CrossRefPubMedGoogle Scholar
  50. 50.
    Miyagawa T, Kawamura H, Obuchi M, Ikesaki A, Ozaki A, Tokunaga K, Inoue Y, Honda M (2013) Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One 8:e53707.  https://doi.org/10.1371/journal.pone.0053707 CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Barateau L, Lopez R, Dauvilliers Y (2016) Management of narcolepsy. Curr Treat Opin Neurol 18:43.  https://doi.org/10.1007/s11940-016-0429-y CrossRefGoogle Scholar
  52. 52.
    Shindler J, Schachter M, Brincat S, Parkes JD (1985) Amphetamine, mazindol, and fencamfamin in narcolepsy. BMJ 290:1167–1170CrossRefPubMedGoogle Scholar
  53. 53.
    Alvarez B, Dahlitz M, Grimshaw J, Parkes JD (1991) Mazindol in long-term treatment of narcolepsy. Lancet Lond Engl 337:1293–1294CrossRefGoogle Scholar
  54. 54.
    Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y (2019) A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol 85:359–370.  https://doi.org/10.1002/ana.25423 CrossRefPubMedGoogle Scholar
  55. 55.
    Sleepfoundation.org (2019) Sleep apnea | National Sleep Foundation. [online] Available: https://www.sleepfoundation.org/sleep-disorders-problems/sleep-apnea
  56. 56.
    Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y (2012) Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 16:431–443.  https://doi.org/10.1016/j.smrv.2011.09.001 CrossRefPubMedGoogle Scholar
  57. 57.
    Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS (2012) Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med 8:451–458.  https://doi.org/10.5664/jcsm.2048 CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Scrima L, Hartman PG, Johnson FH Jr, Hiller FC (1989) Efficacy of gammahydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 26:331–343CrossRefPubMedGoogle Scholar
  59. 59.
    Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J (1993) Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 16:216–220.  https://doi.org/10.1093/sleep/16.3.216 CrossRefPubMedGoogle Scholar
  60. 60.
    US Xyrem Multicenter Study Group (2002) A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25:42–49.  https://doi.org/10.1093/sleep/25.1.42 CrossRefGoogle Scholar
  61. 61.
    US Xyrem Multicenter Study Group (2003) A 12-month, open- label multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 26:31–35.  https://doi.org/10.1093/sleep/26.1.31 CrossRefGoogle Scholar
  62. 62.
    Mayer G, Plazzi G, Iranzo Á, Ortega-Albás J, Quinnell T, Pesch H, Serralheiro P, Schlit AF, Wuiame D, Bentz JWG (2018) Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep 41(9).  https://doi.org/10.1093/sleep/zsy128
  63. 63.
    Pillen S, Pizza F, Dhondt K, Scammell TE, Overeem S (2017) Cataplexy and its mimics: clinical recognition and management. Curr Treat Options Neurol 19:23.  https://doi.org/10.1007/s11940-017-0459-0 CrossRefPubMedGoogle Scholar
  64. 64.
    Wang J, Greenberg H (2013) Status cataplecticus precipitated by abrupt withdrawal of venlafaxine. J Clin Sleep Med 15:715–716.  https://doi.org/10.5664/jcsm.2848 CrossRefGoogle Scholar
  65. 65.
    Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M (2017) The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the committee for medicinal products for human use. Sleep Med 33:125–129.  https://doi.org/10.1016/j.sleep.2017.01.002 CrossRefPubMedGoogle Scholar
  66. 66.
    Szakacs Z, Dauvilliers Y, Mikhaylov V et al (2017) HARMONY-CTP study group. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:200–207.  https://doi.org/10.1016/S1474-4422(16)30333-7 CrossRefPubMedGoogle Scholar
  67. 67.
    Langdon N, Bandak S, Shindler J, Bandak S (1986) Fluoxetine in the treatment of cataplexy. Sleep 9:371–372.  https://doi.org/10.1093/sleep/9.2.371 CrossRefPubMedGoogle Scholar
  68. 68.
    Frey J, Darbonne C (1994) Fluoxetine suppresses human cataplexy: a pilot study. Neurology 44:707–709CrossRefPubMedGoogle Scholar
  69. 69.
    Thirumalai SS, Shubin RA (2000) The use of citalopram in resistant cataplexy. Sleep Med 1:313–316.  https://doi.org/10.1016/S1389-9457(00)00026-5 CrossRefPubMedGoogle Scholar
  70. 70.
    Poryazova R, Siccoli M, Werth E, Basssetti CL (2005) Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 65:967–968.  https://doi.org/10.1212/01.wnl.0000175978.61048.62 CrossRefPubMedGoogle Scholar
  71. 71.
    Schachter M, Parkes JD (1980) Fluvoxamine and clomipramine in the treatment of cataplexy. JNNP 43:171–174Google Scholar
  72. 72.
    Shapiro WR (1975) Treatment of cataplexy with clomipramine. Arch Neurol 32:653–656.  https://doi.org/10.1001/archneur.1975.00490520023002 CrossRefPubMedGoogle Scholar
  73. 73.
    Guilleminault C, Raynal D, Takahashi S, Carskadon M, Dement W (1976) Evaluation of shortterm and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 54:71–87.  https://doi.org/10.1111/j.1600-0404.1976.tb07621.x CrossRefPubMedGoogle Scholar
  74. 74.
    Rugino T (2007) A review of modafinil film-coated tablets for attention deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat 3:293–301PubMedPubMedCentralGoogle Scholar
  75. 75.
    Ivanenko A, Tauman R, Gozal D (2003) Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 4:579–582.  https://doi.org/10.1007/s13311-012-0149-2 CrossRefGoogle Scholar
  76. 76.
    Inocente CO, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimão R, Lin JS, Franco P (2012) Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. ClinNeuropharmacol 35:55–60.  https://doi.org/10.1097/WNF.0b013e318246879d CrossRefGoogle Scholar
  77. 77.
    Moresco M, Pizza F, Antelmi E, Plazzi G (2018) Sodium oxybate treatment in pediatric type 1 narcolepsy. Curr Drug Metab 19:1073–1079.  https://doi.org/10.2174/1389200219666180305153134 CrossRefPubMedGoogle Scholar
  78. 78.
    Murali H, Kotagal S (2006) Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep 29:1025–1029.  https://doi.org/10.1093/sleep/29.8.1025 CrossRefPubMedGoogle Scholar
  79. 79.
    Plazzi G, Clawges HM, Owens JA (2018) Clinical characteristics and burden of illness in pediatric patients with narcolepsy. Pediatr Neurol 85:21–32.  https://doi.org/10.1016/j.pediatrneurol.2018.06.008 CrossRefPubMedGoogle Scholar
  80. 80.
    FDA approves new treatment of cataplexy and excessive daytime sleepiness in pediatric patients with narcolepsy- drug information update [news release] (2018) Silver Spring, MD: FDA Division of Drug InformationGoogle Scholar
  81. 81.
    Nishino S, Kotorii N (2016) Modes of action of drugs related to narcolepsy:pharmacology of wake-promoting compounds and anticataplectics. In: Goswami M, Thorpy MJ, Pandi-Perumal SR (eds) Narcolepsy. A clinical guide. Springer International Publishing, Switzerland, pp 307–329CrossRefGoogle Scholar
  82. 82.
    Dopheide JA, Pilszka SR (2009) Attention-deficit disorder: an update. Pharmacotherapy 29:656–679CrossRefPubMedGoogle Scholar
  83. 83.
    Product information (2007) Dextroamphetamine sulfate oral tablets, dextroamphetamine sulfate oral tablets. St. Louis: Mallinckrodt; 2007Google Scholar
  84. 84.
    Product information (2007) RITALIN: oral tablets, methylphenidate hydrochloride oral tablets. East Hanover, NJ: Novartis; 2007Google Scholar
  85. 85.
    Kotagal S (2018) Treatment of narcolepsy and other organic hypersomnias in children. Paediatr Respir Rev 25:19–24.  https://doi.org/10.1016/j.prrv.2017.06.012 CrossRefPubMedGoogle Scholar
  86. 86.
    Ristanovic RK, Llang H, Hornfeldt CS, Lai C (2009) Exacerbation of cataplexy following gradual withdrawal of antidepressants: manifestation of probable protracted rebound cataplexy. Sleep Med 10:416–421.  https://doi.org/10.1016/j.sleep.2008.04.004 CrossRefPubMedGoogle Scholar
  87. 87.
    Lopez R, Dauvilliers Y (2013) Pharmacotherapy options for cataplexy. Expert Opin Pharmacother 14:895–903.  https://doi.org/10.1517/14656566.2013.783021 CrossRefPubMedGoogle Scholar
  88. 88.
    Ratkiewicz M, Splaingard M (2013) Treatment of cataplexy in a three-year-old using venlafaxine. J Clin Sleep Med 15:1341–1342.  https://doi.org/10.5664/jcsm.3284 CrossRefGoogle Scholar
  89. 89.
    Moller L, Ostergaard J (2009) Treatment with venlafaxine in six cases of children with narcolepsy with cataplexy and hypnagogic hallucinations. J Child Adolesc Psychopharmacol 19:197–201.  https://doi.org/10.1089/cap.2008.036 CrossRefPubMedGoogle Scholar
  90. 90.
    Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F, Mignot E, Cicognani A, Montagna P (2008) Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 255:1549–1554.  https://doi.org/10.1007/s00415-008-0983-7 CrossRefPubMedGoogle Scholar
  91. 91.
    Knudsen S, Biering-Sørensen B, Kornum BR, Petersen ER, Ibsen JD, Gammeltoft S, Mignot E, Jennum PJ (2012) Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology 3:102–103.  https://doi.org/10.1212/WNL.0b013e31825dce03 CrossRefGoogle Scholar
  92. 92.
    Lecendreux M, Berthier J, Corny J, Bourdon O, Dossier C, Delclaux C (2017) Intravenous immunoglobulin therapy in pediatric narcolepsy: a nonrandomized, open-label, controlled, longitudinal observational study. J Clin Sleep Med 15:441–453.  https://doi.org/10.5664/jcsm.6500 CrossRefGoogle Scholar
  93. 93.
    Ruppert E, Zagala H, Chambe J, Comtet H, Kilic-Huck U, Lefebvre F, Bataillard M, Schroder C, Calvel L, Bourgin P (2018) Intravenous immunoglobulin therapy administered early after narcolepsy type 1 onset in three patients evaluated by clinical and polysomnographic follow-up. BehavNeurol15;2018:1671072.  https://doi.org/10.1155/2018/1671072
  94. 94.
    Pizza F, Franceschini C, Peltola H (2013) Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 136:3787–3795.  https://doi.org/10.1093/brain/awt277 CrossRefPubMedGoogle Scholar
  95. 95.
    Donjacour C, Mets MAJ, Verster JC (2010) Narcolepsy, driving and traffic safety. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 217–222CrossRefGoogle Scholar
  96. 96.
    Lindsley G (2010) Narcolepsy, intimacy and sexuality. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 205–216CrossRefGoogle Scholar
  97. 97.
    Naumann A, Bellebaum C, Daum I (2006) Cognitive deficits in narcolepsy. J Sleep Res 15:329–338.  https://doi.org/10.1111/j.1365-2869.2006.00533.x CrossRefPubMedGoogle Scholar
  98. 98.
    Bellebaum C, Daum I (2010) Memory and cognition in narcolepsy. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 223–230CrossRefGoogle Scholar
  99. 99.
    Vignatelli L, Plazzi G, Peschechera F, Delaj L, D’Alessandro R (2011) A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. Sleep Med 12:19–23.  https://doi.org/10.1016/j.sleep.2010.07.008 CrossRefPubMedGoogle Scholar
  100. 100.
    Ingravallo F, Plazzi G (2010) Medico-legal aspects of disability in narcolepsy. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 231–238CrossRefGoogle Scholar
  101. 101.
    Shneerson J (2010) Narcolepsy and mental health. In: Goswami M, Pandi-Perumal SR, Thorpy MJ (eds) Narcolepsy: a clinical guide. Springer Humana Press, New York, pp 239–250CrossRefGoogle Scholar
  102. 102.
    Britton T, Hansen A, Hicks J, Howard R, Meredith A (2002) Guidelines on the diagnosis and management of narcolepsy in adults and children. Evidence-based guidelines for the UK with graded recommendations. Taylor Patten Communications Ltd, AshteadGoogle Scholar
  103. 103.
    Billiard M, QueraSalva M, de Koninck J, Besset A, Touchon J, Cahilhac J (1986) Daytime sleep characteristics and night sleep in the narcoleptic patient. Sleep 9:167–174.  https://doi.org/10.1093/sleep/9.1.167 CrossRefPubMedGoogle Scholar
  104. 104.
    Overeem S, Reading P, Bassetti CL (2012) Narcolepsy. Sleep Med Clin 7:263–281CrossRefGoogle Scholar
  105. 105.
    Krahn LE, Hershner S, Loeding LD, Maski KP, Rifkin DI, Selim B, Watson NF (2015) Quality measures for the care of patients with narcolepsy. J Clin Sleep Med 11:335.  https://doi.org/10.5664/jcsm.4554 CrossRefPubMedGoogle Scholar
  106. 106.
    Mullington J, Broughton R (1993) Scheduled naps in the management of daytime sleepiness in narcolepsy cataplexy. Sleep 16:444–456.  https://doi.org/10.1093/sleep/16.5.444 CrossRefPubMedGoogle Scholar
  107. 107.
    Yuchiyama MG, Mayer G, Meier-Ewert K (1994) Differential effects of extended sleep in narcoleptics patients. Electroencephalogr Clin Neurophysiol 91:212–218CrossRefGoogle Scholar
  108. 108.
    Bhattarai J, Sumerall S (2017) Current and future treatment options for narcolepsy: a review. Sleep Sci 10:19–27.  https://doi.org/10.5935/1984-0063.20170004 CrossRefPubMedGoogle Scholar
  109. 109.
    Rogers AE (1984) Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nurs 16:326–334CrossRefPubMedGoogle Scholar
  110. 110.
    Bruck D, Broughton R (2001) Achieving control over sleepiness in narcolepsy. Aust J Prim Health 7:16–24CrossRefGoogle Scholar
  111. 111.
    Marin-Agudelo H (2011) Multicomponent cognitive behavioral treatment efficacy for narcolepsy (MCBT-N). Sleep Med 12:S55–S42.  https://doi.org/10.1016/j.slsci.2014.07.023 CrossRefGoogle Scholar
  112. 112.
    Conroy DA, Novick DM, Swanson LM (2012) Behavioral management of hypersomnia. Sleep Med Clin 7:325–331CrossRefGoogle Scholar
  113. 113.
    Marín-Agudelo H, Jiménez Correa U (2012) Scheduled naps and systematic desensitization in the emotional processing in patients with narcolepsy: a comparative study of autonomic and cognitive evoked potentials. Sleep 35:A275Google Scholar
  114. 114.
    Marín-Agudelo H, Jiménez Correa U (2013) Beliefs and dysfunctional attitudes in patients with narcolepsy; double-blind study of treatment efficacy. Sleep 36(Suppl: A256)Google Scholar
  115. 115.
    Espana RA, McCormack SL, Mochizuki T, Scammell TE (2007) Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 30:1417–1425.  https://doi.org/10.1093/sleep/30.11.1417 CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Filardi M, Pizza F, Antelmi E, Pillastrini P, Natale V, Plazzi G (2018) Physical activity and sleep/wake behavior, anthropometric, and metabolic profile in pediatric narcolepsy type 1. Front Neurol 9:707.  https://doi.org/10.3389/fneur.2018.00707 CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    MarínAgudelo HA, Jiménez Correa U, Carlos Sierra J, Pandi-Perumal SR, Schenck CH (2014) Cognitive behavioral treatment for narcolepsy: can it complement pharmacotherapy? Sleep Sci 7:30–42.  https://doi.org/10.1016/j.slsci.2014.07.023 CrossRefGoogle Scholar
  118. 118.
    Dennis CL (2003) Peer support within a health care context: a concept analysis. Int J Nurs Stud 40:321–332.  https://doi.org/10.1016/S0020-7489(02)00092-5 CrossRefPubMedGoogle Scholar
  119. 119.
    Embuldeniya G, Veinot P, Bell E, Nyhof-Young J, Sale JE, Britten N (2013) The experience and impact of chronic disease peer support interventions: a qualitative synthesis. Patient Educ Couns 92:3–12.  https://doi.org/10.1016/j.pec.2013.02.002 CrossRefPubMedGoogle Scholar
  120. 120.
    Shilling V, Morris C, Thompson-Coon J, Ukoumunne O, Rogers M, Logan S (2013) Peer support for parents of children with chronic disabling conditions: a systematic review of quantitative and qualitative studies. Dev Med Child Neurol 55:602–609.  https://doi.org/10.1111/dmcn.12091 CrossRefPubMedGoogle Scholar
  121. 121.
    Anderson M, Elliott EJ, Zurynski YA (2013) Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis 8:1–9.  https://doi.org/10.1186/1750-1172-8-22 CrossRefGoogle Scholar
  122. 122.
    Kippola-Pääkkönen A, Härkäpää K, Valkonen J, Tuulio-Henriksson A, Autti-Rämö I (2016) Psychosocial intervention for children with narcolepsy: parents’ expectations and perceived support. J Child Health Care 20:521–529.  https://doi.org/10.1177/1367493516643420 CrossRefPubMedGoogle Scholar
  123. 123.
    Dauvilliers Y, Roth T, Giunta D et al (2017) Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. Sleep Med 40:53–57.  https://doi.org/10.1016/j.sleep.2017.07.030 CrossRefPubMedGoogle Scholar
  124. 124.
    Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, Zee P (2013) Disrupted nighttime sleep in narcolepsy. J Clin Sleep 9:955–965.  https://doi.org/10.5664/jcsm.3004 CrossRefGoogle Scholar
  125. 125.
    European Commission (2014) Implementation report on the commission communication on rare diseases: Europe’s challenges and council recommendation of 8 June 2009 on an action in the field of rare diseases. Available at: http://ec.europa.eu/health/rare_diseases/docs/2014_rarediseases_implementationreport_en.pdf

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Medicine and SurgeryUniversity of ParmaParmaItaly
  2. 2.Department of Biomedical and Neuromotor Sciences, Alma Mater StudiorumUniversity of BolognaBolognaItaly
  3. 3.IRCCS Istituto delle Scienze Neurologiche di BolognaBolognaItaly

Personalised recommendations